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ABSTRACT 
Background: The increasing prevalence of resistance to established anti- 
biotics among key respiratory bacterial pathogens highlights a need for new 
antibacterial gents for the treatment of community-acquired respiratory tract 
infections (RTIs). Ketolides are a new class of antibiotics pecifically developed 
for the treatment of RTIs. 
Objective: The aim of this review was to present he current status of treat- 
ment of RTIs with ketolides, focusing on telithromycin--the first ketolide to be 
approved by the US Food and Drug Administration for clinical use. 
Methods: To gather evidence on the current status of ketolides, a literature 
search was conducted using MEDLINE (years: 1990-2005; key terms: ketolides, 
telithromycin, and HMR364 7). 
Results: Telithromycin shows strong in vitro activity against he major respira- 
tory pathogens, including strains resistant o other antibiotics, as well as the 
atypical respiratory pathogens. The pharmacokinetic properties of telithromycin 
are compatible with once-daily dosing. Clinical trials have demonstrated that 
telithromycin 800 mg QD for 5 to 10 days is effective in the treatment of acute bac- 
terial sinusitis, acute bacterial exacerbations of chronic bronchitis, and mild to 
moderate community-acquired pneumonia. Overall, telithromycin is well tolerated 
by patients. Drug-drug interactions are similar to those reported for macrolides. 
Conclusion: Evidence to date indicates that telithromycin is an effective and 
well-tolerated empiric treatment for community-acquired RTIs. (Curr Ther Res 
Clin Exp. 2005;66:139-153) Copyright © 2005 Excerpta Medica, Inc. 
Key words: respiratory tract infections, antibiotics, ketolides, telithromycin. 
INTRODUCTION 
Community-acquired respiratory tract infections (RTIs), such as acute bacteri- 
al sinusitis (ABS), acute bacterial exacerbations of chronic bronchitis (AECB), 
and community-acquired pneumonia (CAP), are prevalent conditions, account- 
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ing for significant proportions of visits to primary care physicians and anti- 
biotic prescriptions worldwide. 1 In the United States alone, RTIs account for 
-100 million visits each year, at a cost of more than US $1 billion. 2 These condi- 
tions are also associated with significant morbidity and mortality, with AECB 
and CAP together epresenting the most common causes of infection-related 
death in the United States. 1
Antibiotic treatment for community-acquired RTIs is usually empiric because 
the causative pathogen is rarely identified prior to the initiation of antibacte- 
rial therapy in primary care settings. Although community-acquired RTIs are 
caused by a wide variety of organisms, the majority of bacterial infections are 
caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella 
catarrhalis. 1 Although empiric therapy for infection with these organisms i usu- 
ally effective, the increasing prevalence of antibacterial resistance among the 
most common bacterial respiratory pathogens (particularly S pneumoniae) 
may compromise the clinical utility of current standard antibiotics for the treat- 
ment of these conditions. 3 The increasing role of atypical and intracellular 
organisms (eg, Mycoplasma pneumoniae, Chlamydophila [Chlamydia] pneumoniae, 
and Legionella pneumophila) in causing community-acquired RTIs is another 
concern. 3 Such trends highlight a clinical need for new antibiotics for the treat- 
ment of community-acquired RTIs that will provide a tailored spectrum of activ- 
ity against both common and atypical/intracellular respiratory pathogens, in- 
cluding isolates resistant to current reatment options, as well as a low potential 
to induce antibiotic resistance. 
Ketolides, anew class of antibiotics, are structurally related to the macrolides 
but have a number of structural modifications that confer comparatively en- 
hanced activity and a reduced risk for antibiotic resistance. 4 These modifica- 
tions include replacement of the cladinose sugar of the 14-membered ring with 
a keto group. Similar to the macrolides, the ketolides exert their antimicrobial 
activity by binding to the bacterial ribosome and inhibiting protein synthesis. 
Telithromycin is a ketolide distinguishable from the macrolides and other 
ketolides in that it has a side chain at positions Cll and C12. 5 This unique struc- 
ture allows telithromycin to bind strongly to 2 sites on the 23S bacterial ribo- 
some (domains II and V), in contrast o macrolides, which bind strongly to 
domain V but have only weak binding to domain II. 4 Overall, telithromycin binds 
to the bacterial ribosome with 6-fold to 10-fold the affinity of macrolides. 6 This 
stronger interaction with the ribosomal binding site confers activity against 
pathogens resistant o macrolide, lincosamide, and streptogramin B (MLSB) 
antibiotics. With the existence of 2 binding sites, it would be expected that bac- 
teria must mutate at both of these sites to develop resistance to telithromycin. 
However, dual binding alone might not prevent he development of resistance; 
over recent years, resistance to antibiotics with multiple sites of action, such as 
the fluoroquinolones 7 and vancomycin, has emerged. 8 
Although several ketolide agents (including cethromycin) are being assessed 
for use in the treatment of RTIs, telithromycin is the first ketolide to be ap- 
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proved by the US Food and Drug Administration (FDA) for clinical use and is the 
focus of this article. 
To gather data on the current status of ketolide treatments, we conducted 
a literature search using MEDLINE (years: 1990-2005; key terms: ketolides, 
telithromycin, and HMR3647). 
SPECTRUM OF ACTIVITY 
Results of in vitro studies confirm that ketolides possess potent activity against 
both common and atypical/intracellular respiratory pathogens. 9-12 Telithro- 
mycin has improved in vitro activity against S pneumoniae compared with 
macrolides and azalides, including both penicillin-resistant and macrolide- 
resistant strains (Table 0.12'13 Telithromycin is also active against gram-negative 
RTI bacterial pathogens (eg, M catarrhalis, H influenzae) and is not affected 
by [3-1actamase production, making it active against ampicillin-resistant strains 
of these pathogens. 11Telithromycin also has shown in vitro activity against 
Staphylococcus aureus 14 and atypical/intracellular respiratory pathogens (eg, 
M pneumoniae, C pneumoniae)) ° 
Pharmacokinetic and pharmacodynamic studies 15-17 have revealed that te- 
lithromycin concentrations achieved in plasma and respiratory tissues after 
standard 800-rag QD dosing are generally higher than the minimum concentra- 
tion required to inhibit the growth of 90% of bacterial isolates (MlC90) (Table I). 
Cm~ has been shown to be -2 pg/mL in plasma 15 compared with -4, -15, and 
-100 pg/mL in the bronchial mucosa, epithelial lining fluid, and alveolar macro- 
phages, respectively. 16,17 
The in vitro activity of cethromycin appears generally comparable to that 
of telithromycin. 9 Some evidence suggests that cethromycin might be slight- 
ly more active against certain streptococcal nd chlamydial isolates compared 
with telithromycin. 18,19 However, because in vitro activity does not always pre- 
dict in vivo efficacy, the clinical significance of this finding is unknown. 
LOW POTENTIAL TO INDUCE RESISTANCE 
The importance of bacterial resistance cannot be overemphasized. Before 1972, 
H influenzae was almost universally susceptible to ampicillin. However, since 
then, 13-1actamase-producing strains resistant to ampicillin have become com- 
mon. 2° Approximately 25% of H influenzae isolates in the United States are 
resistant to ampicillin. 11 Most recently, mutations in penicillin-binding proteins 
have contributed to increased resistance to 13-1actam antibiotics. 21Ketolides 
appear to have a low potential to induce antibiotic resistance to key respirato- 
ry pathogens because they possess potent bactericidal activity against S pneu- 
moniae, H influenzae, C pneumoniae, and M catarrhalis. 22 Results of an analysis 
of 13,874 isolates of S pneumoniae collected worldwide during the first 3 years 
of the international Prospective Resistant Organism Tracking and Epiclemiology 
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for the Ketolide Telithromycin (PROTEKT) surveillance study 23 found sustained 
activity of telithromycin against S pneumoniae, even in countries where this 
antibiotic was in clinical use. Overall, 99.8% of isolates collected were found 
to be fully susceptible to telithromycin, according to Clinical and Laboratory 
Standards Institute breakpoints (susceptible, MIC _<1 pg/mL; intermediately re- 
sistant, MIC 2 pg/mL; and resistant, MIC _>4 pg/mL). These findings are encourag- 
ing, considering that many patients in Europe had already been exposed to this 
drug. Ketolides do not induce MLS B (target site) resistance, which is encoded 
by the erythromycin-resistant methyltransferase ( rm[B]) gene. MLS B resis- 
tance occurs when domain V of the bacterial ribosome is altered, thereby reduc- 
ing affinity for macrolides. As discussed previously, the novel chemical struc- 
ture of ketolides allows enhanced binding to bacterial ribosomes; therefore, 
antibacterial ctivity is retained against MLSB-resistant isolates. 4 
Although the evidence outlined previously indicates that ketolides have a 
low potential to induce resistance, the true picture will emerge only after 
more widespread clinical use. The extensive and often inappropriate use of 
antibiotics plays a major role in the development of drug resistance. 24It 
should be remembered that previous evidence surrounding the use of new 
antibiotics uggests that resistance can and will develop. Therefore, despite 
the low potential of ketolides to induce resistance, the drugs in this new class 
should be prescribed judiciously to preserve their effectiveness. As with all 
antibiotics, ketolides hould be prescribed only for infections that are proven 
or strongly suspected to be caused by susceptible bacteria nd should not be 
used in suspected viral infections. 25 When choosing the most appropriate 
therapy for community-acquired RTIs, the most likely pathogens and their 
antibiotic susceptibility should be considered. In the absence of microbio- 
logic data, the local antibiotic susceptibility rates among likely causative 
pathogens hould be considered when making treatment decisions. Ketolides 
would appear to be an appropriate alternative treatment option for community- 
acquired RTIs in areas with significant rates of resistance to macrolides and 
[3-1actams among the major causative pathogens (S pneumoniae, H influenzae, 
and M catarrhalis). 
CLINICAL EFFICACY 
To date, telithromycin is the only ketolide to have been evaluated in random- 
ized, controlled clinical trials in patients with community-acquired RTIs. Re- 
suits of published studies show this agent to have efficacy comparable to 
that of current standard treatment of ABS, AECB, and mild to moderate CAP 
(Table II). 2G-39 In all studies, including the pooled analyses ubsequently discussed, 
equivalence was determined on the basis of the 95% CIs of the difference in clin- 
ical efficacy between telithromycin and comparator in the per-protocol study 
population. Equivalence was concluded if the lower limit of the 95% CI was 
___-15% and the upper limit crossed zero. 
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Acute Bacterial Sinusitis 
Three randomized, double-blind studies have evaluated the efficacy of 
telithromycin in ABS. A pooled analysis of the 2 studies comparing different 
treatment durations howed that oral telithromycin 800 mg QD for 5 days was 
as effective as the same dosage of telithromycin for 10 days, with clinical cure 
rates of 83% and 82%, respectively (95% CI, -6.0 to 7.7). 40 Furthermore, the 
causative pathogen was eradicated (or presumed eradicated) in 90% and 91% 
of patients receiving 5-day and 10-day telithromycin. Treatment with telith- 
romycin 800 mg QD for 5 days has also been shown to provide clinical and bacte- 
riologic outcomes imilar to those of 10-day regimens of amoxicillin-clavulanate 
500/125 mg TID or cefuroxime axetil 250 mg BID; clinical cure rates in the per- 
protocol population were 80.9% for telithromycin and 77.4% for pooled com- 
parators (95% CI, -3.8 to 10.7). 4o Clinical cure rates were high for all common 
causative pathogens in these comparative studies, including S pneumoniae (90% 
for 5-day telithromycin and 88% for comparators), H influenzae (82% and 87%, 
respectively), M catarrhalis (100% in both groups), and S aureus (100% and 75%, 
respectively). 4° Telithromycin was also found to be effective for the treatment 
of ABS caused by penicillin-resistant and/or erythromycin-resistant isolates of 
S pneumoniae in these trials. 4° 
Acute Bacterial Exacerbations of Chronic Bronchitis 
A pooled analysis of data from 3 randomized, double-blind, controlled trials 
showed that oral treatment with telithromycin 800 mg QD for 5 days was as ef- 
fective as standard 10-day regimens of cefuroxime axetil 500 mg BID, amoxicillin- 
clavulanate 500/125 mg TID, or clarithromycin 500 mg BID in the treatment of 
AECB. 41 Clinical cure rates were 86% in both the telithromycin and comparator 
groups (95% CI, -4.3 to 4.9), with eradication or presumed eradication of the 
causative pathogen achieved in 80% of telithromycin-treated patients and 82% 
of comparator-treated patients. Clinical cure rates were 82% and 79% for Spneu- 
moniae, 73% and 85% for H influenzae, and 93% and 85% for M catarrhalis for 
telithromycin and comparators, respectively. Clinical cure rates were also com- 
parable between treatment groups in patients with adverse prognostic factors, 
including age >-65 years or a history of chronic obstructive pulmonary disease 
or severe bronchial obstruction (forced expiratory volume in l second/forced 
vital capacity, <60%). Importantly, the shorter duration of telithromycin thera- 
py was not found to be associated with higher rates of relapse or reinfection 
compared with 10-day courses of comparator antibiotics. 
Community-Acquired Pneumonia 
Eight studies have evaluated the efficacy of telithromycin in adult patients 
with mild to moderate CAP. 25,42 Patients received oral telithromycin 800 mg QD 
for 7 to 10 days or standard 10-day therapeutic regimens of amoxicillin 1000 mg 
TID, clarithromycin 500 mg BID, or trovafloxacin 200 mg QD (although this 
study was discontinued prematurely because of concerns about the safety of 
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trovafloxacin). A pooled analysis of data from the 8 trials showed that telithro- 
mycin 800 mg QD for 7 to 10 days was as effective as standard antibacterial ther- 
apy for the treatment of mild to moderate CAP, with overall clinical cure rates 
of 91.0% for telithromycin and 90.4% for comparators (95% CI, -3.6 to 5.0). 42 Clinical 
cure rates with telithromycin for all major CAP pathogens were 94.8% for Spneu- 
moniae, 90.5% for H influenzae, 86.7% for M catarrhalis, and 78.9% for S aureus. 
Clinical cure rates with telithromycin  patients infected with macrolide-resistant 
and penicillin-resistant S pneumoniae were both 89%. It is notable that clinical 
cure rates with telithromycin remained high (92% [33/36]) in patients with mild 
to moderate CAP due to infection with multidrug-resistant S pneumoniae. 25 
Telithromycin was also associated with high rates of clinical cure in patients 
with CAP attributable to infection with atypical pathogens (C pneumoniae, 94% 
[34/36]; Mpneumoniae, 97% [36/37]; and L pneumophila, 100% [13/13]). 42 
TOLERABILITY 
Telithromycin appears to be well tolerated when used to treat community- 
acquired RTIs. A pooled analysis of tolerability data from 4472 patients treated 
with oral telithromycin 800 mg QD for 5 or 7 to 10 days in Phase Ill clinical tri- 
als showed the severity of adverse vents reported uring treatment with this 
ketolide to be predominantly mild or moderate. 25In these controlled, compara- 
tive trials, diarrhea and nausea were the most commonly reported adverse 
events, with respective rates of 10.8% and 7.9% in telithromycin-treated pa- 
tients (n = 2702) and 8.6% and 4.6% in those treated with comparator antibi- 
otics (n = 2139). Few patients withdrew from telithromycin treatment because 
of adverse vents (4.4% compared with 4.3% of those receiving comparators). 
Gastrointestinal events were the most common adverse vents leading to treat- 
ment discontinuation, particularly diarrhea (0.9% for telithromycin and 0.7% for 
comparators) and nausea (0.7% and 0.5%, respectively). Overall, serious ad- 
verse events were rare (0.3%) and most frequently respiratory in nature and 
related to the underlying abnormality. Based on our literature search, no deaths 
possibly related to telithromycin treatment have been reported in published 
clinical trials. 
Abnormal iver function test results, such as increased alanine aminotrans- 
ferase (ALT) or aspartate aminotransferase activity, were usually asymptomatic 
and reversible. ALT levels >3-fold the upper limit of normal were observed in 
1.6% and 1.7% of patients treated with telithromycin and comparators, respec- 
tively. 25 Hepatitis with or without jaundice occurred in 0.07% of patients treat- 
ed with telithromycin and was reversible. 25
Visual adverse vents were seen in 1.1% of telithromycin-treated patients and 
most often included blurred vision, diplopia, and difficulty focusing. The major- 
ity of these events were transient (lasting several hours) and mild to moder- 
ate. 25 Some patients discontinued therapy because of these adverse vents. For 
patients who continued treatment, some adverse events resolved while they 
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were receiving telithromycin, whereas others continued to have symptoms 
until after they had completed the full course of treatment. All drug-related 
cases of blurred vision were reported to have resolved without sequelae. 
As documented for macrolides, fluoroquinolones, and other classes of anti- 
biotics, telithromycin has the potential to prolong the QTc interval on electrocardi- 
ography in some patients. 43 QT interval prolongation may predispose patients to an 
increased risk for ventricular arrhythmias. However, telithromycin administered as 
repeated 800-mg doses or as single doses up to 2400 mg did not increase the QTc 
interval in a study involving healthy oung adults. 44 In addition, no cardiovascular 
morbidity or mortality attributable to QTc prolongation occurred with telithromycin 
treatment in 4780 patients in clinical efficacy trials, including 204 patients having a 
prolonged QTc interval at baseline. 25 Nonetheless, telithromycin should be avoided 
in patients with congenital prolongation of the QTc interval, patients with ongoing 
proarrhythmic conditions (eg, hypokalemia), and patients receiving Class IA (eg, quini- 
dine, procainamide) or Class III (eg, dofetilide, amiodarone) antiarrhythmic agents. 25 
Exacerbations of myasthenia gravis have been reported in patients treated with 
telithromycin; therefore, telithromycin snot recommended in patients with this con- 
dition unless no other therapeutic alternatives are available. 25 Telithromycin is well 
tolerated in elderly patients and those with concomitant conditions uch as renal or 
hepatic impairment, diabetes mellitus, or cardiovascular disease. Studies in special 
patient populations have shown that dosage adjustment is not necessary in patients 
with hepatic impairment or those with mild to moderate renal impairment (creati- 
nine clearance, ->30 mL/min). 45,46 
DRUG INTERACTION POTENTIAL 
The potential for interactions between macrolides and other agents metabo- 
lized by cytochrome P450 (CYP) is well recognized. 47Macrolides appear to form 
intermediate complexes with CYP, inhibiting the metabolism of agents by this 
route. Although telithromycin is a competitive inhibitor of CYP, it does not 
appear to form such inhibitory complexes, suggesting that drug-drug interac- 
tions commonly seen with some macrolides may be less likely to occur during 
treatment with this ketolide. However, the potential for interactions hould be 
considered comparable to that of macrolides until data from wider use become 
available. 
Studies have been undertaken to investigate the potential for drug-drug in- 
teractions with telithromycin. 25Results suggest hat interactions are unlikely 
between telithromycin and oral contraceptives, 48 paroxetine (a CYP2D6 sub- 
strate), 49 antacids (magnesium hydroxide), 5° and ranitidine. 5° In addition, con- 
trolled studies have shown that grapefruit juice, components of which inhibit 
intestinal CYP3A4, 51 has no effect on telithromycin exposure. 25 Interactions 
with theophylline (a CYPIA substrate) also appear unlikely; however, adminis- 
tration of the 2 drugs should be separated by at least 1 hour to reduce the 
potential for gastrointestinal dverse vents. 25 
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Concomitant administration of telithromycin and oral anticoagulants (eg, 
warfarin) may potentiate the effects of the oral anticoagulants; therefore, moni- 
toring of prothrombin times or the international normalized ratio should be 
considered in this situation. 25 For patients coadministered telithromycin and 
digoxin, the adverse events associated with digoxin or serum digoxin levels 
should be monitored. Monitoring (and dosage adjustment if considered neces- 
sary) is also recommended for patients concomitantly administered midazo- 
lam. 25 In patients treated with metoprolol for heart failure, increased exposure 
to metoprolol may be of clinical importance. Therefore, coadministration of
telithromycin and metoprolol in patients with heart failure should be consid- 
ered with caution. Coadministration of telithromycin and rifampin (and other 
CYP3A4 inducers) should be avoided. Concomitant reatment with telithro- 
mycin and simvastatin, a hydroxymethylglutaryl coenzyme A reductase inhibi- 
tor (statin) metabolized via CYP3A4, increased levels of simvastatin by 5-fold 
to 8-fold. 25 Therapy with simvastatin or other statins that are metabolized by 
CYP3A4 (lovastatin and atorvastatin) should be suspended while patients are 
receiving telithromycin treatment. 25Little or no interaction is expected with flu- 
vastatin, pravastatin, or rosuvastatin because CYP3A4 is not a major metabolic 
pathway for these agents. Coadministration of telithromycin with cisapride and 
pimozide is contraindicated. 25 
POSTAUTHORIZATION SURVEILLANCE 
Telithromycin has been authorized for clinical use in a number of countries 
since its initial launch in Germany in October 2001. The results of a study con- 
ducted in Germany involving >34,000 patients who received telithromycin 
for the treatment of community-acquired RTIs between October 2001 and 
December 200352 have confirmed the clinical efficacy and tolerability data for 
telithromycin observed in clinical trials. In this study, clinical cure rates 
(patients assessed as cured or improved following once-daily treatment for 
5-7 days, depending on indication) for patients with ABS, AECB, or mild to mod- 
erate CAP were all >98%. Adverse drug reactions (mostly gastrointestinal) oc- 
curred in 1.85% of all patients. 
Data on resistance rates were not available. 
CONCLUSIONS 
The ketolides, of which telithromycin was the first to be FDA approved for clinical 
use, have been specifically developed for the empiric treatment of community- 
acquired RTIs. Available data show that telithromycin possesses potent in vitro 
antibiotic activity against common respiratory pathogens, including isolates 
resistant o other antibiotics, as well as atypical/intracellular o ganisms. Al- 
though in vitro data may not always predict in vivo activity, the available clini- 
cal data support the in vitro findings. Results from randomized, controlled 
149 
CURRENT THERAPEUTIC RESEARCH 
studies have shown that tel i thromycin 800 mg QD was as effective and well 
to lerated as current standard t reatment  of ABS, AECB, and mild to moderate  
CAP. Moreover, clinical and bacteriologic efficacy appear  to be maintained in 
patients with infections caused by penicillin-resistant and/or erythromycin- 
resistant pathogens. Available data confirm that tel i thromycin has a low poten- 
tial to induce resistance or to select for cores istance to MLS B antibiotics both 
in vitro and in vivo. Many factors in addition to efficacy and tolerabil ity influ- 
ence the choice of antibiotic. With clinical efficacy similar to current standard 
therapies and a once-daily dosing regimen, tel i thromycin would appear  to be 
a viable empir ic t reatment  option for outpat ients with community-acquired 
RTIs, such as ABS, AECB, and mild to moderate  CAP. Its effectiveness against 
macrol ide-resistant pneumococca l  infections makes tel i thromycin a reasonable 
alternative to f luoroquinolones for the t reatment  of these infections. However, 
it will be important  o use tel i thromycin judiciously to preserve its effective- 
ness and prevent resistance and to remain aware of its potential  to interact with 
commonly  used drugs, such as certain statins. 
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